Otonomy (NASDAQ:OTIC) & Bio-Path (NASDAQ:BPTH) Financial Comparison
Otonomy (NASDAQ:OTIC) & Bio-Path (NASDAQ:BPTH) Financial Comparison
Otonomy (NASDAQ:OTIC – Get Rating) and Bio-Path (NASDAQ:BPTH – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.
Otonomy（纳斯达克股票代码：OTIC — 获取评级）和Bio-Path（纳斯达克股票代码：BPTH — 获取评级）都是小型医疗公司，但哪只股票更好？我们将根据两家企业的收益、股息、盈利能力、分析师建议、机构所有权、风险和估值来对比这两家企业。
Analyst Recommendations
分析师建议
This is a summary of recent ratings and target prices for Otonomy and Bio-Path, as reported by MarketBeat.com.
据Marketbeat.com报道，这是Otonomy和Bio-Path最近的评级和目标价格的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Otonomy | 0 | 2 | 1 | 0 | 2.33 |
| Bio-Path | 0 | 0 | 1 | 0 | 3.00 |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 自治学 | 0 | 2 | 1 | 0 | 2.33 |
| 生物路径 | 0 | 0 | 1 | 0 | 3.00 |
Otonomy currently has a consensus target price of $3.25, suggesting a potential upside of 3,182.83%. Bio-Path has a consensus target price of $9.00, suggesting a potential upside of 306.32%. Given Otonomy's higher possible upside, analysts plainly believe Otonomy is more favorable than Bio-Path.
Otonomy目前的共识目标价为3.25美元，这表明潜在的上涨空间为3,182.83％。Bio-Path的共识目标价为9.00美元，这表明潜在的上涨空间为306.32％。鉴于Otonomy可能有更高的上行空间，分析师显然认为Otonomy比Bio-Path更有利。
Volatility and Risk
波动性和风险
Valuation and Earnings
估值和收益
This table compares Otonomy and Bio-Path's revenue, earnings per share (EPS) and valuation.
该表比较了Otonomy和Bio-Path的收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Otonomy | $130,000.00 | 49.60 | -$51.18 million | ($0.77) | -0.13 |
| Bio-Path | N/A | N/A | -$10.44 million | ($1.97) | -1.12 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 自治学 | 130,000.00 美元 | 49.60 | -5118 万美元 | (0.77 美元) | -0.13 |
| 生物路径 | 不适用 | 不适用 | -1,044 万美元 | (1.97 美元) | -1.12 |
Bio-Path has lower revenue, but higher earnings than Otonomy. Bio-Path is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.
Bio-Path的收入较低，但收入却高于Otonomy。Bio-Path的市盈率低于Otonomy，这表明它目前是这两只股票中更实惠的一只。
Insider & Institutional Ownership
内部所有权和机构所有权
41.2% of Otonomy shares are owned by institutional investors. Comparatively, 6.4% of Bio-Path shares are owned by institutional investors. 9.1% of Otonomy shares are owned by company insiders. Comparatively, 3.5% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Otonomy的41.2％股份由机构投资者持有。相比之下，Bio-Path的6.4％股份由机构投资者持有。9.1％的Otonomy股份由公司内部人士持有。相比之下，3.5％的Bio-Path股份由公司内部人士持有。强大的机构所有权表明，大型基金经理、捐赠基金和对冲基金认为一家公司已为长期增长做好了准备。
Profitability
盈利能力
This table compares Otonomy and Bio-Path's net margins, return on equity and return on assets.
该表比较了Otonomy和Bio-Path的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Otonomy | N/A | -137.86% | -68.50% |
| Bio-Path | N/A | -67.16% | -62.17% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 自治学 | 不适用 | -137.86% | -68.50% |
| 生物路径 | 不适用 | -67.16% | -62.17% |
Summary
摘要
Otonomy beats Bio-Path on 7 of the 11 factors compared between the two stocks.
在两只股票的11个因素中，Otonomy在7个因素上击败了Bio-Path。
About Otonomy
关于自主学
(Get Rating)
（获取评分）
Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.
Otonomy, Inc. 是一家生物制药公司。从事神经病学疗法的开发。该公司的产品线包括OTIVIDEX（地塞米松）梅尼尔病、OTIPRIO（环丙沙星视力悬浮液）急性带管中耳炎（AOMT）、OTO-313（加环素）耳鸣、OTO-413（BDNF）隐性听力损失、OTO-510（耳保护剂）预防CIHL、OTO-6XX（毛细胞再生）严重听力损失。它以奥蒂普里奥品牌运营。该公司由 Jay B. Lichter、Jeffrey Harris、Rick Friedman 和 Allen F. Ryan 于 2008 年 5 月 6 日创立，总部位于加利福尼亚州圣地亚哥。
About Bio-Path
Bio-Path
(Get Rating)
（获取评分）
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
Bio-Path Holdings, Inc. 是一家生物技术公司，从事急性髓系白血病（AML）和慢性髓系白血病（CML）疗法的开发。其产品线包括 Prexigebersen、BP1002 和 BP1003。该公司由彼得·尼尔森、道格拉斯·莫里斯、加布里埃尔·洛佩兹-贝雷斯泰因和安娜·塔里·阿希泽于2007年5月10日创立，总部位于德克萨斯州贝莱尔。
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Otonomy及相关公司的最新新闻和分析师评级的简明每日摘要。